University of South Australia, Clinical and Health Sciences, Adelaide 5000, Australia; Basil Hetzel Institute for Translational Health Research, Woodville 5011, Australia.
University of South Australia, Clinical and Health Sciences, Adelaide 5000, Australia.
J Control Release. 2022 Jun;346:300-316. doi: 10.1016/j.jconrel.2022.04.035. Epub 2022 Apr 28.
Antimicrobial photodynamic therapy (aPDT) has emerged as a promising approach to aid the fight against looming antibiotic resistance. aPDT harnesses the energy of light through photosenstizers to generate highly reactive oxygen species that can inactivate bacteria and fungi with no resistance. To date aPDT has shown great efficacy against microbes causing localized infections in the skin and the oral cavity. However, its wide application in clinical settings has been limited due to both physicochemical and biological challenges. Over the past decade nanomaterials have contributed to promoting photosensitizer performance and aPDT efficiency, yet further developments are required to establish accredited treatment options. In this review we discuss the challenges facing the clinical application of aPDT and the opportunities that nanotechnology may offer to promote the safety and efficiency of aPDT.
抗菌光动力疗法(aPDT)作为一种有前途的治疗方法,有助于对抗日益严重的抗生素耐药性。aPDT 通过光敏剂利用光的能量来产生具有高反应性的氧物种,从而可以使细菌和真菌失活而不产生耐药性。迄今为止,aPDT 已显示出对抗引起皮肤和口腔局部感染的微生物的巨大疗效。然而,由于物理化学和生物学方面的挑战,其在临床环境中的广泛应用受到限制。在过去的十年中,纳米材料有助于提高光敏剂的性能和 aPDT 的效率,但仍需要进一步的发展来建立可靠的治疗选择。在这篇综述中,我们讨论了 aPDT 临床应用所面临的挑战以及纳米技术可能提供的机会,以促进 aPDT 的安全性和效率。